Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.28 CHF | +8.82% | +4.75% | +47.07% |
04-17 | Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member | CI |
03-19 | Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 22
Sales per Business
CHF in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Drugs
100.0
%
| 6 | 100.0 % | 9 | 100.0 % | +43.85% |
Sales per region
CHF in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Italy & United States
100.0
%
| 6 | 100.0 % | 9 | 100.0 % | +43.85% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 60 | 12-05-14 |
Luca Benatti
FOU | Founder | 63 | 97-12-31 |
Roberto Galli
DFI | Director of Finance/CFO | - | 01-12-31 |
Filippo Moriggia
COO | Chief Operating Officer | - | 16-10-31 |
Ravi Anand
CTO | Chief Tech/Sci/R&D Officer | 67 | 04-12-31 |
Laura Faravelli
PRN | Corporate Officer/Principal | - | 18-12-31 |
Dennis Dionne
PRN | Corporate Officer/Principal | - | 14-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 07-12-31 | |
Luca Benatti
FOU | Founder | 63 | 97-12-31 |
Ulrich Köstlin
CHM | Chairman | 71 | 12-12-31 |
Stefan Weber
CEO | Chief Executive Officer | 60 | 12-05-14 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 18,631,834 | 17,069,414 ( 91.61 %) | 0 | 91.61 % |
Company contact information
Sector
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+47.07% | 148M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- NWRN Stock
- Company Newron Pharmaceuticals S.p.A.